Contact PI/Project LeaderABDULKADIR, SARKI A. Other PIs
Awardee OrganizationNORTHWESTERN UNIVERSITY AT CHICAGO
Description
Abstract Text
OVERALL: ABSTRACT
This application is a request for renewal funding of the SPORE in Prostate Cancer P50 CA180995 at the Robert
H. Lurie Comprehensive Cancer Center of Northwestern University in collaboration with the University of Chicago
Comprehensive Cancer Center and NorthShore University HealthSystem, an affiliate of the University of
Chicago. The SPORE first received support from the National Cancer Institute in 2001; a renewal application
was funded in 2009. In 2015, we were the recipients of a new SPORE and we are now requesting continued
funding for this program. Our SPORE unites basic scientists, clinicians, pathologists, biostatisticians,
bioinformaticists and advocates from our academic institutions, all of whom are dedicated to advancing
translational prostate cancer research. In this application we propose three highly translational and innovative
research projects that have both basic science and clinical science co-leadership: Project 1: Targeting the MYC
Pathway in Prostate Cancer (Abdulkadir, Hussain); Project 2: Re-directing the sensitivity of metastatic
castration-resistant prostate cancer to immunotherapy (Wu, Sosman, Morgans); Project 3: STING Activation to
Overcome Resistance to Immune Checkpoint Blockade in PTEN-deficient Prostate Cancer (Patnaik, Gajewski,
Stadler). Three core facilities support the proposed research projects: Administrative, Leadership and Advocacy
(Abdulkadir, Hussain, Stadler); Biostatistics/Bioinformatics (Kocherginsky, Zhao) and Biospecimen (Yang).
Internal and External Advisory Boards provide a source of scientific input to members of the SPORE team on a
biannual and yearly basis, respectively. Our Advocacy Group are well established in the SPORE arena and
make a valued contribution to our success. The SPORE includes Developmental Research and Career
Enhancement Programs, both of which provide a source of innovation and new discoveries. All together, we
anticipate that the results obtained from our research endeavors will have a significant impact on the health of
patients diagnosed with prostate cancer.
Public Health Relevance Statement
OVERALL: PROJECT NARRATIVE
The SPORE in Prostate Cancer brings together basic scientists, clinicians, pathologists, biostatisticians,
bioinformaticists and advocates who together will work to improve the outcome of patients with prostate cancer
through experiments to understand the basic biology and through the design and conduct of innovative
paradigm-shifting clinical trials.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AdvocacyAdvocateAggressive courseAmericanAntibody TherapyAntitumor ResponseBasic ScienceBioinformaticsBiologyBiometryBiopsy SpecimenBlood specimenCancer EtiologyCancer PatientCatchment AreaChicagoClinicalClinical SciencesClinical TrialsCollaborationsCombined Modality TherapyComprehensive Cancer CenterCore FacilityDNA DamageDedicationsDevelopmentDiagnosisDiseaseFDA approvedFamily memberFocus GroupsFriendsFundingGenetic TranscriptionHealthHealth systemHumanImmune systemImmunotherapyInfrastructureInnovative TherapyInstitutionLeadershipMHC Class I GenesMalignant neoplasm of prostateMeasurableMeasuresMediatingMetastatic Prostate CancerMyelogenousNational Cancer InstituteOncogenicPIK3CG genePTEN genePathologistPathway interactionsPatient CarePatient-Focused OutcomesPatientsPharmacologic SubstancePhase I Clinical TrialsPhosphorylationPoly(ADP-ribose) Polymerase InhibitorPre-Clinical ModelProstate specific antigen measurementQualifyingQuality of lifeRegulationRejuvenationResearchResearch PersonnelResearch Project GrantsResistanceSTING agonistsScientistSignal TransductionSourceT cell infiltrationT-Cell Activation PathwayTalentsTestingTherapeuticTissuesTranslatingTranslational ResearchTranslationsTreatment EfficacyUniversitiesVisceralWorkandrogen independent prostate canceranti-cancer researchbonec-myc Genescancer geneticscareercohortdesignefficacy evaluationexperienceexperimental studyhumanized monoclonal antibodiesimmune checkpoint blockadeimprovedimproved outcomeinhibitorinnovationinvestigator-initiated trialmembermenmortalitymouse modelnew technologynovelnovel strategiesnovel therapeuticspatient populationpre-Investigational New Drug meetingpreclinical studyprogrammed cell death protein 1programsprostate cancer modelrecruitsafety studysuccesstargeted treatmenttumortumor microenvironmenttumor-immune system interactions
No Sub Projects information available for 5P50CA180995-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P50CA180995-09
Patents
No Patents information available for 5P50CA180995-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P50CA180995-09
Clinical Studies
No Clinical Studies information available for 5P50CA180995-09
News and More
Related News Releases
No news release information available for 5P50CA180995-09
History
No Historical information available for 5P50CA180995-09
Similar Projects
No Similar Projects information available for 5P50CA180995-09